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Abstract
The Hsp90 family proteins Hsp90, Grp94, and TRAP1 are present in the cell cytoplasm, endoplasmic reticulum, and
mitochondria, respectively; all play important roles in tumorigenesis by regulating protein homeostasis in response to
stress. Thus, simultaneous inhibition of all Hsp90 paralogs is a reasonable strategy for cancer therapy. However, since
the existing pan-Hsp90 inhibitor does not accumulate in mitochondria, the potential anticancer activity of pan-Hsp90
inhibition has not yet been fully examined in vivo. Analysis of The Cancer Genome Atlas database revealed that all
Hsp90 paralogs were upregulated in prostate cancer. Inactivation of all Hsp90 paralogs induced mitochondrial
dysfunction, increased cytosolic calcium, and activated calcineurin. Active calcineurin blocked prosurvival heat shock
responses upon Hsp90 inhibition by preventing nuclear translocation of HSF1. The purine scaffold derivative DN401
inhibited all Hsp90 paralogs simultaneously and showed stronger anticancer activity than other Hsp90 inhibitors. Pan-
Hsp90 inhibition increased cytotoxicity and suppressed mechanisms that protect cancer cells, suggesting that it is a
feasible strategy for the development of potent anticancer drugs. The mitochondria-permeable drug DN401 is a newly
identified in vivo pan-Hsp90 inhibitor with potent anticancer activity.
Introduction
Heat shock protein 90 (Hsp90) family members are
ATP-dependent molecular chaperones that regulate the
stability and function of client proteins involved in
growth, survival, and adaptation of cancer cells to cellular
stress1–3. Hsp90 family proteins comprise four paralogs,
each of which resides at different subcellular locations:
Hsp90α/β in the cytoplasm, glucose-regulated protein 94
(Grp94) in the endoplasmic reticulum (ER), and tumor
necrosis factor receptor-associated protein-1 (TRAP1) in
mitochondria. Each Hsp90 paralog plays a crucial role in
tumor progression, multidrug resistance, increased cell
death threshold, and metastasis4–8. Thus, simultaneous
inactivation of all Hsp90 family proteins can compromise
multiple tumorigenic pathways operating in different
cellular compartments; this approach is very likely to
increase anticancer activity above that afforded by
paralog-specific inactivation of Hsp90 family proteins.
Overall, Hsp90 paralogs have a similar structure and
very high similarity with respect to the ATP binding
pockets at the N-terminal domains (NTDs)9,10. Therefore,
many Hsp90 inhibitors targeting the ATP binding pocket
exhibited cross-reactivity against both Grp94 and TRAP1
in vitro; such agents are known as pan-Hsp90 inhibitors11.
Recently, however, we demonstrated that current pan-
Hsp90 inhibitors do not inactivate TRAP1 significantly
in vivo due to inefficient accumulation of the drug inside
mitochondria12,13. Thus, the reported cellular activity of
most Hsp90 inhibitors originates primarily from inacti-
vation of cytosolic and/or ER Hsp90 paralogs, not from
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inactivation of mitochondrial TRAP1. Thus, no study has
yet examined the anticancer activity of actual pan-Hsp90
family protein inhibitors, meaning that the therapeutic
potential/benefits of simultaneous inactivation of all
Hsp90 family proteins have never been explored.
Since Hsp90 was identified as a potential cancer target,
various inhibitors targeting cytoplasmic Hsp90 have been
developed as anticancer agents1–3,14. So far, at least 18
different inhibitors with desirable pharmacological prop-
erties, including ganetespib (STA-9090), have been eval-
uated in clinical trials, but none have shown satisfactory
efficacy to be approved by the FDA. The main reason for
the limited efficacy can be attributed to the dose-limiting
toxicity at the drug dose of near-complete client depletion
and the inevitable activation of HSF1, leading to cyto-
protective heat shock responses15–17.
HSF1 is a transcription factor that causes heat shock
responses such as induction of Hsp27, Hsp40, and Hsp70
to allow cells to adapt to proteotoxic stresses18,19. These
target genes of HSF1 have powerful cytoprotective func-
tions, including anti-apoptosis, drug resistance, and pro-
liferative effects20. Upon proteotoxic stress, Hsp90 binds
to unfolded client proteins and dissociates HSF1 from
HSP90, which in turn induces translocation of HSF1 to
the nucleus and subsequent expression of heat shock
response genes. Similarly, Hsp90 inhibitors trigger dis-
sociation of HSF1 from Hsp90 and activate the pro-
survival heat shock response, which is a mechanical
drawback and an unavoidable adverse effect of current
Hsp90 inhibitors19,21,22. Thus, coinhibition of HSF1 has
been suggested to improve the anticancer activity of
Hsp90 inhibitors23,24.
Calcineurin is a calcium-dependent serine/threonine
protein phosphatase whose activation inhibits that of
HSF125–27. Activated calcineurin dephosphorylates and
subsequently suppresses nuclear translocation of HSF1. In
addition to its antitumorigenic roles, calcineurin supports
protumorigenic pathways by activating nuclear factor of
activated T cells (NFAT). Critically, activation and nuclear
translocation of NFAT is regulated by the phosphoryla-
tion status of the transcription factor28. Among Hsp90
client proteins, Akt inactivates glycogen synthase kinase
3β (GSK3β), which triggers NFAT export to suppress its
transcriptional activity. Thus, complex regulatory net-
works involving protumorigenic transcription factors
HSF1 and NFAT would be markedly affected by dysre-
gulation of calcium homeostasis and Hsp90.
Here, we show that simultaneous inactivation of Hsp90
paralogs localized within different cellular compartments
not only increases anticancer activity but also dysregulates
calcium homeostasis. In addition, activation of HSF1 and
NFAT was suppressed by dysregulation of calcium and
Hsp90 homeostasis, which further increases the antic-
ancer activity of Hsp90 inhibitors.
Materials and methods
Cells and culture conditions
Human cervical (HeLa), liver (SK-HEP-1, HepG2), brain
(A172), kidney (ACHN), lung (H460), and prostate
(22Rv1) cancer cells were purchased from the American
Type Culture Collection (ATCC) and maintained as
recommended by the supplier. Cells were cultured at
37 °C in a humidified atmosphere of 5% CO2 and in
DMEM or RPMI medium (GIBCO) containing 10% fetal
bovine serum (FBS; GIBCO) and 1% penicillin/strepto-
mycin (GIBCO). Human RWPE-1 and corneal cells were
purchased from ATCC and cultured in ATCC corneal
medium (ATCC). Primary hepatocytes were isolated from
8-week-old BALB/c mice, as described previously13{Park,
2014 #17}{Park, 2014 #17} and cultured in M199/EBSS
medium (HyClone) containing 10% FBS at 37 °C/5% CO2.
Chemicals and antibodies
All chemicals were purchased from Sigma. Anti-
TRAP1, anti-Hsp90, anti-Cyt c, anti-Hsp70, anti-Drp1,
and anti-Bax antibodies were purchased from BD Bios-
ciences; anti-Grp94, anti-Akt, anti-Chk1, anti-c-FLIP,
anti-HER2, anti-Sorcin, and anti-SDHB antibodies were
purchased from Santa Cruz Biotechnology; anti-PHB,
anti-pS9-GSK3β, anti-GSK3β, anti-COX-2, anti-HSF1,
anti-SIRT3, and anti-calcineurin A antibodies were pur-
chased from Cell Signaling Technology; an anti-
calcineurin regulatory subunit B antibody was purchased
from Sigma; an anti-CypD antibody was purchased from
Thermo; and an anti-β-actin antibody was purchased
from MP Biomedicals.
Cellular calcineurin activity assays
Cellular calcineurin activity was measured using a cal-
cineurin phosphatase assay kit (ENZO Life Sciences).
Colorimetric assays were performed at a wavelength of
620 nm using a microplate spectrophotometer (TECHAN
Infinite M200). Absorbance values were normalized to
protein concentrations, and calcineurin activity was
expressed relative to that in DMSO-treated samples.
siRNA treatment
Small interfering RNAs (siRNA) specific for calcineurin,
ryanodine receptor 2 (RyR2), cyclophilin D (CypD),
TRAP1, and Grp94 were synthesized by Genolution
(Korea). siRNAs targeting CypD and calcineurin reg-
ulatory subunit B (CNB) were synthesized by Genolution
(Korea) using the following sequences: CNB-#1 5′-
GCCTGAGTTACAACAGAATCCTTTA -3′ and CNB-#2
5′-GGAACAATCTGAAAGATACACAGTT-3′; RyR2-#1
5′-AAGTGGTTCTGCAGTGCACCG; RyR2-#2 5′-AAG
TACGAGTTGGAGATGACC; CypD-#1 5′-GGCAGAT
GTCGT-CCCAAAG-3′ and CypD-#2 5′-GATAAGGG
CTTCGGCTACA-3′; Grp94-#1 5′- TCGCCTCAGTTT
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GAACATTGA and Grp94-#2 5′- GAGAGAGGAAGA
AGCTATT; TRAP1-#1 5′-AAACATGAGTTCCAGGCC
GAG and TRAP1-#2 5′-CCCGGTCCCTGTACTCAG
AAA; and control 5′-ACUCUAUCUGCACGCUGAC-3′.
Cells were cultured on six-well plates until they reached
50–75% confluence, transfected for 48 h with 20 nM
siRNA mixed with G-Fectin (Genolution), and then trea-
ted with drugs as indicated.
Protein purification and fluorescence polarization assays
Recombinant full-length TRAP1, Hsp90α, and GST-
Grp94 were prepared as described previously13. During
preparation, the recombinant GST-Grp94 protein was
eluted with a buffer containing 10mM glutathione as the
last step. The fluorescence probe PU-H71-FITC3 was
synthesized as described previously and used to measure
fluorescence polarization13. Briefly, 10 nM PU-H71-
FITC3 and 100 nM protein were incubated for 24 h at
4 °C with various concentrations of inhibitor in FP buffer
containing 135 mM NaCl, 4.3 mM Na2HPO4, 2.7 mM
KCl, 1.4 mM KH2PO4, 2 mM MgCl2, 1 mM DTT, 0.1 mg/
mL BSA, and 0.05% NP40 (pH 7.3). Fluorescence polar-
ization was measured in a SYNERGY NEO microplate
reader (BioTek Instruments, Inc.).
Analyses of cell viability and apoptosis induction
Cell viability was examined using 3(4,5-dimethyl-thy-
zoyl-2-yl)2,5 diphenyltetrazolium bromide (MTT) assays
and quantified by measuring the absorbance of the tet-
razolium dye at 595 nm in a SYNERGY NEO microplate
reader (BioTek Instruments, Inc.). Absorbance values
were normalized to those of the DMSO control, and the
data were expressed as percentage viability. To measure
apoptosis induction, caspase activation (DEVDase activ-
ity) and the DNA content (propidium iodide) of labeled
cells were analyzed using a FACSCalibur™ flow cytometer
(BD Biosciences). Data were processed using FlowJo
software (TreeStar). In situ direct DNA fragmentation was
analyzed using an in situ cell death detection kit (Roche)
and an FV1000 laser confocal scanning microscope
(Olympus).
Live cell imaging
Cytoplasmic calcium concentrations were determined
as previously described29. Briefly, HeLa cells were
labeled for 30 min with 5 μM Fura-2 and incubated at
37 °C/5% CO2 in calcium-free Locke’s solution con-
taining 154 mM NaCl, 5.6 mM KCl, 3.2 mM MgCl2,
5 mM HEPES, 10 mM glucose, and 0.2 mM EGTA (pH
7.4). After drug treatment, changes in fluorescence were
monitored every 5 min using an IX81 ZDC microscope
(Olympus) at an emission wavelength of 510 nm, with
dual excitation at 340 and 380 nm. Images of 340/380
fluorescence ratios were generated and analyzed using
the Xcellence software package (Olympus). To detect
HSF1 localization, HeLa cells were transfected with an
HSF1–GFP plasmid30 obtained from Addgene (Addgene
plasmid #32538) using the Lipofectamine transfection
reagent (Invitrogen). After transfection for 24 h, cells
were treated with the indicated drugs and then analyzed
using an IX81 ZDC (Olympus). To visualize mito-
chondrial structure, HeLa cells were stained for 20 min
with 200 nM MitoTracker dye, treated with the drugs,
and then analyzed under an LSM 780 confocal micro-
scope (Zeiss).
Immunohistofluorescence staining of prostate tumor
specimens
Human specimens were provided by the Korea Pros-
tate Bank through the Infrastructure Project for Basic
Science of the MEST, Korea. Experiments using tumor
tissues from patients with prostate cancer (PCa) were
approved by the Institutional Review Board (IRB) of
UNIST (IRB no. 1044216-13-07-C). Formalin-fixed,
paraffin-embedded tissue samples from patients were
obtained from the Korea Prostate Bank (Seoul, Korea).
Sections were deparaffinized by incubation at 60 °C for
2 h and then rehydrated through a series of graded
ethanol solutions, culminating in water alone. Antigen
retrieval was performed in 10 mM sodium citrate (pH
6.0) for 40 min using a conventional pressure cooker.
Cells were permeabilized with 0.5% Triton X-100 for
10 min and then blocked with blocking solution (5%
BSA, 5% FBS, 0.3% Triton X-100) for 1 h at room tem-
perature. Dual-immunostaining was performed using
anti-mouse Hsp90/anti-rabbit TRAP1 and anti-mouse
TRAP1/anti-rabbit Grp94 antibodies, followed by Alexa-
488 and Alexa-594 conjugated secondary antibodies.
Stained tissues were analyzed using an Axio zoom
microscope (Zeiss).
RNA extraction and reverse transcription-polymerase chain
reaction (RT-PCR)
Total RNA was prepared from cultured cells using
RNeasy mini kits (QIAGEN), and cDNA was synthesized
using the ProtoScript® First Strand cDNA Synthesis Kit
(New England Biolabs) and an oligo (dT) primer. PCR
reactions were performed in a Master cycler PCR machine
(Eppendorf) with the following sets of oligonucleotide
primers: GAPDH, 5′-CGGGAAGCTTGTCATCAATG
G-3′ and 5′-GGCAGTGATGGCATGGACTG-3′; Hsp27,
5′-GAGTGGTCGCAGTGGTTAGG-3′ and 5′-ACAGG
GAGGAGGAAACTTGG-3′; Hsp40, 5′-GGAAAGAG
CATTCGAAACGA-3′ and 5′-ATGCCAGGCCTGATAA
CATC-3′; Hsp70, 5′-CCAGCTGAAGAAGGGTCAAG-3′
and 5′-TTTTCTGCTGGTGTCTGCTG-3′; and Hsp90,
5′-CTGGGTTTCCTCAGGAT-3′ and 5′-TACCGGATT
TTGTCCAATGC-3′.
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Tumor xenograft experiments
All experiments involving animals were approved by the
Ulsan National Institute of Science and Technology
(UNIST, UNISTIACUC-16-27). Cancer cells (7 × 106
22Rv1) were suspended in 200 μL of PBS and then
injected subcutaneously into both flanks of 6-week-old
BALB/c nu/nu male mice (Charles River Laboratories).
Tumors were allowed to grow to an average volume of
approximately 100mm3. Next, animals were grouped
randomly (two tumors/mouse, five mice/group). Subse-
quently, vehicle (DMSO), DMAG, and gamitrinib were
dissolved in 20% Cremophor EL (Sigma) in PBS. DMAG
and/or gamitrinib (10 mg/kg) were administered intra-
peritoneally twice a week. Tumors were measured using
calipers, and tumor volumes were calculated using the
following formula: V= 1/2 × (width)2 × length. At the end
of the experiment, animals were euthanized, and organs
(brain, heart, kidney, liver, lung, spleen, stomach, and
tumor) were collected for histology and western blot
analysis. In addition, harvested organ specimens were
fixed in 10% formalin and embedded in paraffin for his-
tological analyses. Briefly, Section (5 μm thick) were
placed on high-adhesive slides, stained with H&E, and
scanned at ×20 magnification using the Dot slide system
(Olympus). For western blot analyses, tissue samples were
homogenized in RIPA buffer containing 50 mM Tris (pH
8.0), 150mM NaCl, 1% NP-40, and 0.25% N-deox-
ycholate, plus protease inhibitor and phosphatase inhi-
bitor cocktails (Calbiochem).
Data from The Cancer Genome Atlas (TCGA)
The Cancer Genome Atlas (TCGA) level 3 PCa RNAseq
data were downloaded from the Broad Institute GDAC
FireBrowse (http://firebrowse.org, data version:
2016_01_28). Data were quantified at the gene level using
RSEM and normalized using the Upper Quartile method,
RPKM (reads per million of mapped reads per kilobase of
transcript length), and the ACTB gene. Among 550 sam-
ples obtained, 52 pairs of cancer and matched normal
samples were used for analysis.
Statistical analyses
MTT experiments were conducted in duplicate and
repeated independently at least three times. Statistical
analyses were performed using the software program
Prism 7.0 (GraphPad). Differences were identified using
unpaired t-tests and were considered significant at p <
0.05.
Results
Increased expression of Hsp90, Grp94, and TRAP1 in
human PCa specimens
We analyzed PCa RNAseq data from The Cancer
Genome Atlas (TCGA) to examine the expression of
Hsp90α (HSP90AA1), Hsp90β (HSP90AB1), Grp94
(HSP90B1), and TRAP1 (TRAP1). The expression of
genes in tumors was significantly higher than that in
normal tissues (Fig. 1a). Although some Hsp90 inhibitors
inhibit all Hsp90 family proteins in vitro, they are unable
to inhibit mitochondrial Hsp90 in vivo due to inefficient
accumulation inside mitochondria13,31. Thus, we analyzed
the pairwise expression of Hsp90 paralogs between Hsp90
inhibitor-inhibited Hsp90/Grp94 and noninhibited
TRAP1. Pairwise comparison revealed a strong positive
correlation between TRAP1 and other Hsp90 paralogs;
Spearman’s correlation coefficients (r) for Hsp90α,
Hsp90β, and Grp94 were 0.6213, 0.7356, and 0.5773,
respectively (Fig. 1b). Consistent with these data, tumor
regions in human PCa specimens showed higher expres-
sion of Hsp90(α/β), Grp94, and TRAP1 proteins than
normal surrounding tissues (Fig. 1c, d). Further analyses
of the confocal fluorescence microscopy images revealed a
significant positive correlation between TRAP1 expres-
sion and that of Hsp90 (r= 0.3301) and Grp94 (r=
0.6656) at a single cancer cell level (Fig. 1d). Taken
together, these data indicate increased expression of all
Hsp90 paralogs in tumors and suggest that inactivation of
all Hsp90 paralogs could increase anticancer activity.
Combination treatment with TRAP1 and Hsp90 inhibitors
induces apoptosis in vitro and in vivo
To examine the effect of simultaneous inactivation of all
Hsp90 paralogs in cancer cells, we treated HeLa cells with
Hsp90 inhibitors (to inactivate Hsp90s localized in the
cytoplasm and ER) and gamitrinib (to inactivate the
mitochondrial pool of Hsp90s, including TRAP1)31,32. All
Hsp90 inhibitors showed increased cytotoxic effects when
combined with gamitrinib (Fig. 2a). This increased cyto-
toxicity of the drug combination was confirmed in A172,
NCI-H460, SK-HEP-1, 22Rv1, and HeLa cells (brain, lung,
liver, prostate, and cervical cell lines, respectively) (Fig.
2b). Mathematical analysis using combination index (CI)
values33 showed that the effect of the drug combination
was synergistic, i.e., CI values in cancer cells were > 0.75
(Fig. 2c and Supplementary Table 1). However, drug
synergism was not detected when used to treat normal
prostate epithelial cells (RWPE-1) and human corneal
cells (Fig. 2d). Combined drug treatment resulted in
marked elevation of active caspase-3 (Fig. 2e) and dis-
charge of mitochondrial cytochrome c (Cyt c) (Fig. 2f),
suggesting a synergistic increase in apoptosis induction.
Similarly, a pan-caspase inhibitor (z-VAD-fmk) led to a
marked reduction in cytotoxicity induced by the drug
combination (Supplementary Fig. 1). Consistent with
in vitro experiments, drug combinations also suppressed
the growth of 22Rv1 cells implanted subcutaneously into
nude mice to a greater extent than single agent treatments
(Fig. 2g); no significant weight loss (Fig. 2h) or organ
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toxicity was observed (Supplementary Fig. 2a). In addi-
tion, combined drug administration led to a marked
increase in the number of TUNEL+ apoptotic cells in the
22Rvl mouse xenograft model (Fig. 2i; Supplementary Fig.
2b) when compared with that in the control.
Combined drug treatment alters the phosphorylation of
HSF1
To better understand the molecular mechanisms
underlying drug synergism, we first analyzed client
protein degradation and induction of heat shock
Fig. 1 Hsp90 paralogs are coexpressed in prostate tumors. a Expression of mRNA encoding Hsp90 gene family members obtained from TCGA
RNAseq data. Expression of mRNA encoding HSP90AA1, HSP90AB1 (Hsp90α/β), HSP90B1 (Grp94), and TRAP1 (TRAP1) in cancer and normal tissues from
52 patients with prostate cancer; **p < 0.005, ****p < 0.0001. b Correlation between HSP90AA1 and TRAP1 (left), HSP90AB1 and TRAP1 (middle), and
HSP90B1 and TRAP1 (right) expression in the TCGA RNAseq database. c Expression of Hsp90 paralogs in human prostate cancer specimens. The
boundary between the normal (N) and tumor (T) regions is indicated. Tumor specimens were analyzed by immunofluorescence staining with anti-
TRAP1, anti-Hsp90, and anti-Grp94 antibodies, and protein expression in single cells was analyzed by confocal microscopy. Scale bar, 1 mm.
d Expression of TRAP1 vs. Hsp90 (left) and TRAP1 vs. Grp94 (right). Tumor specimens were analyzed as in c. Data from 87 cells are presented in scatter
plots. Pearson correlation coefficient (r) and p values are indicated.
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Fig. 2 Synergistic anticancer effects of combined treatment with gamitrinib and Hsp90 inhibitors. a Combined treatment with Hsp90
inhibitors plus gamitrinib. HeLa cells were treated with 5 μM gamitrinib and 10 μM Hsp90 inhibitors for 24 h and then analyzed by the MTT assay.
b Effect of combined drug treatment on various cancer cell lines. 22Rv1 cells were treated for 24 h with 2.5 μM gamitrinib and 5 μM DAMG, and other
cells were treated with 5 μM gamitrinib and 10 μM DMAG, either alone or in combination, and then analyzed by the MTT assay. c Synergistic
cytotoxic activity. HeLa and 22Rv1 cells were treated with various concentrations of DMAG in the presence of 2.5, 5, and 10 μM gamitrinib and then
analyzed by the MTT assay. d Cytotoxicity against human normal cells. Primary human corneal cells and normal human prostate normal cells (RWPE-
1) were treated for 24 h with drugs and then analyzed by the MTT assay. e Induction of apoptosis. HeLa cells were treated for 24 h with 5 μM
gamitrinib and 10 μM DMAG, either alone or in combination, stained with propidium iodide (PI) and FITC-DEVD-fmk, and then analyzed by flow
cytometry. f Cytochrome c (Cyt C) discharge from mitochondria. HeLa cells were treated for 18 h with drugs, and cytosolic fractions were analyzed by
western blotting. g Tumor xenograft experiment. 22Rv1 cells were implanted subcutaneously into nude mice. Mice received 10 mg/kg DMAG (i.p.)
and 10 mg/kg gamitrinib (i.p.), either alone or in combination, twice/week. Tumor volume was assessed daily by caliper measurement. Three mice per
group/two tumors per animal. h Body weight changes were measured prior to sacrifice. i Apoptosis of tumor tissues was analyzed by the TUNEL
assay. All data represent the mean ± SEM; *p < 0.05, ****p < 0.0001.
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responses in cancer cells after paralog-specific inacti-
vation18. As reported previously, treatment with gami-
trinib or siRNA targeting TRAP1 degraded its client
proteins (SDHB, SIRT3, and Sorcin), and treatment with
an Hsp90/Grp94 inhibitor, DMAG, induced degradation
of the respective client proteins (Akt, Chk1 and HER2)
(Supplementary Fig. 3a, b)7,9,34–36. HER2 is a client
protein of both Grp94 and Hsp90; thus, treatment with
PU-WS137 or siRNA targeting Grp94 induced specific
degradation of HER2 (Supplementary Fig. 3a, c). DMAG
increased Hsp70 expression in addition to the induction
of client proteins, whereas gamitrinib had no effect (Fig.
3a). All data were consistent with those in a previous
report of the effects of paralog-specific inhibition in
cancer cells19. Interestingly, however, DMAG did not
increase the expression of heat shock proteins such as
Hsp70, Hsp27, Hsp40, and Hsp90 in the presence of
gamitrinib (Fig. 3a, b), suggesting a lack of Hsp90
inhibitor-triggered heat shock responses after pan-
Hsp90 inhibition. The transcription factor HSF1 is
hyperphosphorylated prior to translocation from the
cytoplasm to the nucleus, resulting in the expression of
heat shock proteins upon Hsp90 inhibition19,24. DMAG
treatment alone not only increased nuclear localization
but also retarded migration of HSF1 in SDS-PAGE gels;
by contrast, the DMAG–gamitrinib combination
increased HSF1 migration to a greater extent than
DMAG alone and inhibited nuclear localization of HSF1
(Fig. 3c, d). These data strongly suggest that defective
nuclear localization is caused by altered posttransla-
tional modification of HSF1.
Combination drug treatment activates calcineurin, which
suppresses HSF1 activation
Since phosphorylation regulates nuclear localization of
HSF137–40 and inactivating TRAP1 increases cyto-
plasmic calcium concentrations29, we hypothesized that
a calcium-regulated phosphatase could play a role in
HSF1 regulation. An inhibitor of the protein phospha-
tase calcineurin, namely, FK50641, reversed the effects of
combined drug treatment on HSF1 migration sig-
nificantly (Fig. 3d), suggesting that calcium and calci-
neurin regulate HSF1. Consistent with this, combined
drug treatment led to a marked increase in calcineurin
activity, which was completely inhibited by treatment
with FK506 (Fig. 4a). Genetic knockdown of endogenous
calcineurin restored the drug combination-induced
reduction in Hsp70 expression (Fig. 4b) and sig-
nificantly reduced the cytotoxicity of the drugs against
cancer cells (Fig. 4c). There was no change in the
Fig. 3 Combined drug treatment inhibits the nuclear localization of HSF1 and suppresses the induction of Hsp70. a Suppression of Hsp70 in
cancer cells by combined drug treatment. HeLa, A172, HepG2, and 22Rv1 cells were treated for 6 h with gamitrinib and DMAG and then analyzed by
western blotting. b Expression of HSF1 target genes. 22Rv1 cells were treated for 6 h with gamitrinib and DMAG, and total RNA was isolated and
analyzed by reverse transcription PCR. c Nuclear translocation of HSF1. HeLa cells showing transient expression of HSF1-GFP were treated for 6 h with
5 μM gamitrinib and 10 μM DMAG, either alone or in combination, and then analyzed by confocal microscopy. Bar, 20 µm. d Hyperphosphorylation
of HSF1. HeLa cells were treated for 6 h with gamitrinib, DMAG, and FK506 as indicated. The nuclear fraction (upper) and whole cellular extracts
(lower) were analyzed by western blotting.
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expression of calcineurin protein after combined drug
treatment, suggesting altered phosphatase activity of
calcineurin (Supplementary Fig. 4a). The data indicate
that combined drug treatment-induced cytotoxicity
against cancer cells is dependent on the function of
calcium-activated calcineurin.
Fig. 4 Drug-induced calcium-dependent calcineurin activity promotes cell death. a Calcineurin activity. HeLa cells were treated with drugs for
6 h. Calcineurin activity in total cell extracts was analyzed using a calcineurin phosphatase assay kit. Activity was expressed relative to that in DMSO-
treated controls. b Suppression of Hsp70 by calcineurin silencing. Cells were treated for 24 h with control or calcineurin regulatory subunit (CNB)
siRNAs, incubated for 6 h with drugs, and then analyzed by western blotting. c Effects of combined drug treatment in the absence of CNB. Cells were
treated for 24 h with control or CNB siRNAs, incubated for 24 h with 5 μM gamitrinib and 10 μM DMAG, and then analyzed by the MTT assay.
d Cytoplasmic calcium release. HeLa cells were stained with Fura-2AM after treatment for 6 h with 5 μM gamitrinib, 10 μM DMAG, and 10 μM PU-
WS13 and then analyzed by fluorescence microscopy. Bar, 50 µm. e Fura-2AM staining after CypD knockdown. Control or CypD siRNA-transfected
cells were treated for 6 h with 5 μM gamitrinib and 10 μM DMAG and then analyzed by fluorescence microscopy. f Fura-2AM staining after RyR2
knockdown. Control or RyR2 siRNA-transfected cells were treated for 6 h with 5 μM gamitrinib and 10 μM DMAG and then analyzed by fluorescence
microscopy. g Hsp70 expression after CypD silencing. After treatment with control or CypD siRNAs, HeLa cells were incubated for 6 h with drugs and
then analyzed by western blotting. h Hsp70 expression after RyR2 silencing. After treatment with control or RyR2 siRNAs, cells were incubated for 6 h
with drugs and analyzed by western blotting. In a, c, the data are presented as the mean ± SEM; ***p < 0.001. In e, f, the data are presented as the
mean ± SEM of two independent experiments and were collected from 40 cells; ****p < 0.0001.
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Inhibition of TRAP1 and Grp94 causes a synergistic
increase in calcium release from mitochondria and the ER,
respectively
Previous studies report that Grp94 and TRAP1 play
roles in calcium homeostasis in the ER and mitochondria,
respectively, which are the major calcium-storing orga-
nelles29,42,43. Therefore, to examine the effect of inhibiting
Grp94 and TRAP1 on cytoplasmic calcium elevation, we
exclusively inhibited Grp94 using the specific inhibitor
PU-WS137 or Grp94-targeting siRNAs. In combination
with gamitrinib treatment, inhibition of Grp94 was suffi-
cient to elevate cytoplasmic calcium concentrations (Fig.
4d; Supplementary Fig. 4b, c), suggesting that cancer cells
require the chaperone activities of Grp94 and TRAP1 to
maintain cellular calcium homeostasis by preserving the
proteostasis of respective organelles. Previously, we
showed that TRAP1 inactivation increased cytoplasmic
calcium concentrations via calcium-induced calcium
release mechanisms involving the mitochondria and ER
calcium transporters mitochondrial cyclophilin D (CypD)
and ER RyR2, respectively29. Consistent with this, we
found that increases in cytoplasmic calcium in HeLa cells
were markedly reduced after genetic knockdown of either
CypD or RyR2 (Fig. 4e, f). Furthermore, deficiency of
either CypD or RyR2 reversed Hsp70 expression induced
by combined drug treatment (Fig. 4g, h), indicating that
coordinated calcium discharge between the mitochondria
and ER is crucial for suppression of HSF1-dependent heat
shock responses mediated by calcineurin activity.
Akt inhibition blocks calcineurin-induced NFAT survival
signals
Calcineurin dephosphorylates and activates NFAT by
triggering its nuclear translocation; this may have protu-
morigenic effects by supporting the proliferation and
survival of cancer cells44. Thus, we examined whether
activated calcineurin increases the transcriptional activity
of NFAT after combined drug treatment. As reported
previously, ionomycin-induced increases in cytoplasmic
calcium were sufficient to trigger expression of the NFAT
target genes COX-2 and c-FLIP in HeLa cells (Supple-
mentary Fig. 5a)45–47. Similarly, NFAT activation was
observed in HeLa cells after inhibition of Grp94 and
TRAP1 (Fig. 5a). However, pan-Hsp90 inhibition via
combined treatment with DMAG and gamitrinib did not
increase the expression of COX-2 and c-FLIP (Fig. 5a).
The data strongly suggested that Hsp90 participates in the
NFAT activation pathway, probably in an indirect man-
ner, by regulating the activities of its client proteins. Since
Akt is an Hsp90 client protein that inactivates glycogen
synthase kinase 3β (GSK3β) by phosphorylating residue
Ser948, we speculated that Akt suppressed the activity of
Fig. 5 Akt inactivation blocks calcium/calcineurin-induced NFAT survival signals by activating GSK3β. a Decreased calcineurin/NFAT
signaling upon degradation of Akt induced by Hsp90 inhibition. HeLa cells were incubated for 6 h with drugs and then analyzed by western blotting.
b Decreased calcineurin/NFAT signaling upon Akt inactivation. HeLa cells were incubated for 6 h with drugs and then analyzed by western blotting.
c Ionomycin induces calcium-mediated NFAT signaling. HeLa cells were incubated for 6 h with drugs and then analyzed by western blotting.
d GSK3β-mediated NFAT signaling in cancer cells after combined drug treatment. HeLa and 22Rv1 cells were incubated for 6 h with drugs and then
analyzed by western blotting. e Overview of Hsp90 paralog inactivation and NFAT signaling.
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GSK3β (an antagonist of NFAT) to maintain active
NFAT. Consistently, expression of the inactive phosphor-
form of GSK3β was reduced after inhibition of all Hsp90
family proteins (DMAG+Gami; Fig. 5a, b) or Hsp90
alone (DMAG; Fig. 5a) but was not reduced in the
absence of Hsp90 inhibition (Gami, PU-WS13, or PU-
WS13+Gami; Fig. 5a). The data strongly indicate that
pan-Hsp90 inhibition, due to the degradation of Akt,
activates GSK3β and subsequently inhibits NFAT. Like-
wise, degradation or inhibition of Akt was closely asso-
ciated with a reduction in the level of phosphor-GSK3β
and was sufficient to reduce the expression of NFAT
target genes (Fig. 5b, c). Additionally, treatment with the
GSK3β inhibitor Bio49 fully reversed NFAT inactivation
caused by pan-Hsp90 inhibition (Fig. 5d). The cytotoxic
activity of the DMAG–gamitrinib combination was higher
than that of the PU-WS13-gamitrinib combination
(Supplementary Fig. 5b), and the cytotoxic activity of the
PU-WS13-gamitrinib combination was dramatically
improved when cells were cotreated with an Akt1/2
inhibitor (Supplementary Fig. 5c), suggesting that Akt
inactivation is important for improving the anticancer
activity of pan-Hsp90 inhibition. Taken together, the data
argue that the synergistic cytotoxic effects resulting from
simultaneous inactivation of Hsp90, Grp94, and TRAP1
are due to impaired calcium homeostasis and disruption
of Hsp90 client protein networks in cancer cells (Fig. 5e).
Combined drug treatment promotes mitochondrial
dysfunction
Cytoplasmic calcium regulates a variety of cellular
processes, including mitochondrial fusion/fission
dynamics, which is closely related to the control of cell
death pathways50,51. Combined treatment with gamitrinib
and DMAG induced mitochondrial fragmentation to a
greater extent than single agent treatment; however, this
was reversed by the calcium chelator BAPTA-2AM
(Supplementary Fig. 6a), suggesting calcium-induced
mitochondrial fragmentation. Calcineurin depho-
sphorylates dynamin-related protein 1 (Drp1), a central
regulator of the mitochondrial fission process, resulting in
its translocation to the mitochondria and subsequent
mitochondrial fission52. Consistent with this, combined
drug treatment increased the accumulation of Drp1 in the
mitochondria (Supplementary Fig. 6b); treatment with a
Drp1-specific inhibitor (Mdivi-1)53 and siRNA reduced
the effects of combined drug treatment on mitochondrial
fragmentation (Supplementary Fig. 6c, d). Mitochondrial
translocation of Drp1 triggers apoptosis via mitochondrial
recruitment of Bax54. Likewise, treatment with the Drp1
inhibitor Mdivi-1 reduced mitochondrial recruitment of
Bax and subsequent discharge of cytochrome c after
combined drug treatment (Supplementary Fig. 6e). Inhi-
biting calcineurin using siRNAs reduced the
mitochondrial fragmentation induced by combined drug
treatment (Supplementary Fig. 6f), suggesting that acti-
vated calcineurin is responsible for mitochondrial
recruitment of Drp1. Furthermore, the cytotoxic effects of
combined drug treatment fell significantly after treatment
with Mdivi-1, FK506, or BAPTA (Supplementary Fig. 6g).
Taken together, these data suggest that activation of cal-
cineurin by combined drug treatment promotes mito-
chondrial fragmentation by recruiting Drp1 to the
mitochondria to further augment cytotoxicity against
cancer cells.
DN401 inhibits all Hsp90 paralogs simultaneously in vivo
According to our data, the anticancer activity of current
Hsp90 inhibitors can be improved if mitochondrial
TRAP1 is inactivated. Thus, we analyzed Hsp90 inhibitors
to examine their ability to inhibit mitochondrial TRAP1
and identified DN40112 as showing inhibitory activity
against all paralogs in vivo (Fig. 6a). DN401 strongly
inhibited TRAP1 and Grp94 and weakly inhibited Hsp90
in vitro (Fig. 6b). Similar to combined treatment with
DMAG and gamitrinib, DN401 degraded client proteins
of Hsp90 (Akt, Chk1, and HER2), Grp94 (Her2) and
TRAP1 (SIRT3, Sorcin, and SDHB) without inducing
Hsp70, suggesting that the drug is an in vivo pan-Hsp90
family protein inhibitor (Supplementary Fig. 7a). DN401
treatment increased cellular calcium concentrations and
calcineurin activity (Fig. 6c, d); ablation of calcineurin by
siRNA reversed the DN401-mediated suppression of
Hsp70 (Fig. 6e). In addition, because Akt was degraded,
DN401 did not increase c-FLIP, which is a target gene of
NFAT signaling (Supplementary Fig. 7a). Furthermore,
DN401 treatment increased mitochondrial fragmentation
(Fig. 6f) and increased apoptotic cell death (Fig. 6g), which
was reduced by knockdown of calcineurin (Fig. 6f, g and
Supplementary Fig. 7b). Collectively, the data show that
DN401 inhibits Hsp90, Grp94, and TRAP1 (which are
localized in different cellular organelles) simultaneously
in vivo, thereby increasing the anticancer activity of the
drug via a mechanism similar to that underlying combi-
nation treatment with DMAG and gamitrinib.
Discussion
Here, we showed that the anticancer activity of the
current Hsp90 inhibitors can be improved by inhibiting
mitochondrial TRAP1. Experimental data generated using
genetic knockdown and specific inhibitors targeting
individual Hsp90 paralogs indicate that simultaneous
inactivation of all Hsp90 family proteins (Hsp90, Grp94,
and TRAP1) induces not only individual cellular
compartment-specific proteotoxic stresses but also
increases cytoplasmic calcium in cancer cells. The
calcium-activated protein phosphatase calcineurin com-
pletely suppressed the major adverse effects of Hsp90
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inhibition (HSF1 activation). The pyrazolopyrimidine
scaffold inhibitor DN401 inhibited all Hsp90 paralog
proteins in vivo, thereby increasing anticancer activity.
Considering that client proteins of Hsp90 family pro-
teins are involved in multiple tumorigenic pathways in
different cellular compartments, simultaneous inactiva-
tion of all Hsp90 family proteins (pan-Hsp90 inhibition) is
expected to show more potent anticancer activity than
single paralog-specific inhibition. This occurs through
disruption of multiple tumor-supporting pathways within
each organelle. Our experimental data show that, as
expected, pan-Hsp90 inhibition not only induced the
degradation of client proteins in individual organelles but
also discharged calcium from the ER and mitochondria
due to the compromised functions of Grp94 and TRAP1.
The discharged calcium played important roles in
Fig. 6 DN401 is a potent pan-inhibitor of Hsp90 family proteins, resulting in increased calcineurin activity. a Structure of DN401. b Binding
affinity of DN401 for full-length TRAP1, Hsp90, and GST-Grp94. Fluorescence polarization was measured using purified recombinant proteins and PU-
H71-FITC3. The results were compared with maximum and minimum millipolarization (mP) values and presented as the mean ± SEM of two
independent experiments. c Fluo-4 AM staining. HeLa cells were treated for 6 h with 10 μM gamitrinib, 20 μM DMAG, and 20 μM DN401. Fluo-4 AM-
loaded HeLa cells were analyzed by flow cytometry (BD FACSCalibur™) by gating on living cells. d Calcineurin phosphatase activity. HeLa cells were
treated for 6 h with 10 μM AUY922, 5 μM gamitrinib, 10 μM DMAG, 10 μM DN401, and 10 μM FK506. Calcineurin activity in total cell extracts was
analyzed using calcineurin phosphatase assay kits. Activity is shown relative to that in DMSO-treated controls; data are presented as the mean ± SEM.
e Effect of DN401 on HSF1 signaling. HeLa cells were treated for 24 h with control or CNB-#1 siRNA, incubated with drugs (10 μM) for 6 h and then
analyzed by western blotting. f Calcineurin-mediated mitochondrial fragmentation. HeLa cells were treated for 24 h with control or calcineurin
subunit B (CNB) siRNAs. MitoTracker-loaded HeLa cells were treated for 6 h with DMSO or 10 μM DN-401 and then analyzed by confocal microscopy.
Bar, 5 μm. g Calcineurin-mediated cytotoxicity. HeLa cells were treated for 24 h with 10 μM DN401 in the presence of control, CNB-1, or CNB-2 siRNAs,
stained with PI/Annexin V, and analyzed by flow cytometry (BD FACSCalibur™).
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amplifying organelle-specific stresses through activation
of calcineurin, which consequently suppressed prosurvival
signals (HSF1 activation) and switched on additional cell
death signals (translocation of mitochondrial Bax after
Drp1 activation). Although calcineurin activates pro-
survival NFAT, calcineurin activation after pan-Hsp90
inhibition did not activate NFAT because Hsp90 inhibi-
tion degraded its client protein Akt, which is required for
NFAT activation. Thus, multiple inhibitory effects of pan-
Hsp90 inhibition on spatially separated chaperones led to
potent anticancer effects.
Our conclusions raise an important question that has
been ignored during the development of Hsp90 inhibitors
but can affect both the mechanism of drug action and the
anticancer activity of drugs markedly: are Hsp90 inhibi-
tors capable of inactivating all Hsp90 family proteins
within different cellular compartments of cancer cells?
According to our experimental data13,31, the current
Hsp90 inhibitors are unable to inhibit the mitochondrial
pool of Hsp90 (TRAP1) in vivo due to inefficient drug
accumulation inside mitochondria. It is very evident that
Hsp90 inhibitors with TRAP1 inhibitory activity in vivo
will show stronger anticancer activity than those without
TRAP1 inhibitory activity. The next important question is
as follows: is it possible to develop real pan-Hsp90 inhi-
bitors that function in vivo? Here, we showed that DN401
is indeed a pan-Hsp90 inhibitor with potent anticancer
activity in vivo. Since DN401 is a derivative of the well-
known purine scaffold Hsp90 inhibitors PU-H71 and
BIIB-02112, it is not only a proof-of-concept pan-Hsp90
inhibitor but also provides experimental evidence that the
development of such drugs is feasible.
Taken together, our data clearly show that simultaneous
inactivation of Hsp90 paralogs is cytotoxic to cancer cells
without inducing protective mechanisms such as Hsp70
expression. Therefore, increasing the in vivo TRAP1-
inhibiting activity of current Hsp90 inhibitors is a feasible
and effective strategy for developing potent anticancer
therapeutics.
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